Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07923567 (Pfizer)
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
PF-07923567 (also known as BNT167) is an investigational nucleoside-modified messenger RNA (modRNA) vaccine candidate developed by Pfizer and BioNTech for the prevention of shingles (herpes zoster) in healthy adults. The vaccine utilizes the same mRNA technology platform as the Comirnaty COVID-19 vaccine, delivering genetic instructions for the Varicella Zoster Virus (VZV) glycoprotein E (gE) via lipid nanoparticles. Glycoprotein E is a critical antigen for inducing both neutralizing antibodies and T-cell mediated immune responses. By expressing this antigen in host cells, the vaccine aims to bolster the immune system's ability to prevent the reactivation of latent VZV, which causes shingles. It is currently being evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, and immunogenicity profile compared to existing standard-of-care shingles vaccines.
- Other names
- Pfizer-BioNTech shingles vaccineVZV modRNA vaccinemodRNA shingles vaccineBNT167b1BNT-167b1BNT 167b1
02
Targets
RSV N (Respiratory syncytial virus nucleoprotein)gE (VZV glycoprotein E)
Beyond the preview
Go deeper on PF-07923567 (Pfizer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07923567 (Pfizer).